{"id":{"repo_id":"nus","oai_identifier":"oai:scholarbank.nus.edu.sg:10635/214498"},"canonical_url":"https://search.dev.ndltd.org/etd/nus/oai:scholarbank.nus.edu.sg:10635/214498","repository":{"repo_id":"nus","name":"National University of Singapore","base_url":"https://scholarbank.nus.edu.sg/oai/request"},"display":{"title":"MANIPULATING CELL STATES FOR LEUKAEMIA DIFFERENTIATION THERAPY USING NETWORK PHARMACOLOGY","abstract":"Acute myeloid leukaemia (AML) is a rapidly fatal blood cancer which is characterized by the accumulation of immature myeloid cells in the blood and bone marrow as a result of blocked differentiation. In this proof-of-concept study, we demonstrate a novel utility of the MOGRIFY® algorithm in identifying combinations of transcription factors (TFs) and drugs which induce granulocytic differentiation of the NB4 acute promyelocytic leukaemia (APL) cell line. Connectivity Map (CMAP) analysis of these TFs and their target networks identified dimaprit and mebendazole as a drug combination which induces myeloid differentiation. Alternatively, we show that genetic and pharmacologic manipulation of MOGRIFY-identified TFs, specifically MYC and IRF1, also leads to co-operative induction of differentiation in APL cells. We also outline potential mechanisms by which MYC down-regulates IRF1 expression in NB4 cells. We anticipate that MOGRIFY could be used to discover TF-based differentiation therapies for other subtypes of leukaemia or cancers.","abstract_html":"Acute myeloid leukaemia (AML) is a rapidly fatal blood cancer which is characterized by the accumulation of immature myeloid cells in the blood and bone marrow as a result of blocked differentiation. In this proof-of-concept study, we demonstrate a novel utility of the MOGRIFY® algorithm in identifying combinations of transcription factors (TFs) and drugs which induce granulocytic differentiation of the NB4 acute promyelocytic leukaemia (APL) cell line. Connectivity Map (CMAP) analysis of these TFs and their target networks identified dimaprit and mebendazole as a drug combination which induces myeloid differentiation. Alternatively, we show that genetic and pharmacologic manipulation of MOGRIFY-identified TFs, specifically MYC and IRF1, also leads to co-operative induction of differentiation in APL cells. We also outline potential mechanisms by which MYC down-regulates IRF1 expression in NB4 cells. We anticipate that MOGRIFY could be used to discover TF-based differentiation therapies for other subtypes of leukaemia or cancers.","abstract_has_math":false,"creators":["LEE LIN MING"],"institution":null,"degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2021,"date_issued":"2021-07-28","date_published":"2021-07-28","updated_at":"2026-07-24T03:32:30Z","subjects":["Leukaemia, differentiation, pharmacology, transcription, drugs, cancer"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":null,"outbound_label":null,"outbound_source":null},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:creator","label":"Author","values":["LEE LIN MING"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.issued","label":"Date","values":["2021-07-28"]},{"key":"dc:relation.isreferencedby","label":"Dc Relation Isreferencedby","values":["https://scholarbank.nus.edu.sg/handle/10635/214498"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Leukaemia, differentiation, pharmacology, transcription, drugs, cancer"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://scholarbank.nus.edu.sg/bitstreams/7ec1d0e7-1009-4ef3-85ef-fb5630fff113/download"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Acute myeloid leukaemia (AML) is a rapidly fatal blood cancer which is characterized by the accumulation of immature myeloid cells in the blood and bone marrow as a result of blocked differentiation. In this proof-of-concept study, we demonstrate a novel utility of the MOGRIFY® algorithm in identifying combinations of transcription factors (TFs) and drugs which induce granulocytic differentiation of the NB4 acute promyelocytic leukaemia (APL) cell line. Connectivity Map (CMAP) analysis of these TFs and their target networks identified dimaprit and mebendazole as a drug combination which induces myeloid differentiation. Alternatively, we show that genetic and pharmacologic manipulation of MOGRIFY-identified TFs, specifically MYC and IRF1, also leads to co-operative induction of differentiation in APL cells. We also outline potential mechanisms by which MYC down-regulates IRF1 expression in NB4 cells. We anticipate that MOGRIFY could be used to discover TF-based differentiation therapies for other subtypes of leukaemia or cancers."]},{"key":"dc:format.checksum.md5","label":"Dc Format Checksum Md5","values":["7e762c797196a3b398de0e1505cdbb77","3d7706d0015be65305d0aed45aa43487"]},{"key":"dc:title","label":"Title","values":["MANIPULATING CELL STATES FOR LEUKAEMIA DIFFERENTIATION THERAPY USING NETWORK PHARMACOLOGY"]}]}],"canonical_facts":{"dc:creator":["LEE LIN MING"],"dc:date.issued":["2021-07-28"],"dc:description.abstract":["Acute myeloid leukaemia (AML) is a rapidly fatal blood cancer which is characterized by the accumulation of immature myeloid cells in the blood and bone marrow as a result of blocked differentiation. In this proof-of-concept study, we demonstrate a novel utility of the MOGRIFY® algorithm in identifying combinations of transcription factors (TFs) and drugs which induce granulocytic differentiation of the NB4 acute promyelocytic leukaemia (APL) cell line. Connectivity Map (CMAP) analysis of these TFs and their target networks identified dimaprit and mebendazole as a drug combination which induces myeloid differentiation. Alternatively, we show that genetic and pharmacologic manipulation of MOGRIFY-identified TFs, specifically MYC and IRF1, also leads to co-operative induction of differentiation in APL cells. We also outline potential mechanisms by which MYC down-regulates IRF1 expression in NB4 cells. We anticipate that MOGRIFY could be used to discover TF-based differentiation therapies for other subtypes of leukaemia or cancers."],"dc:format.checksum.md5":["7e762c797196a3b398de0e1505cdbb77","3d7706d0015be65305d0aed45aa43487"],"dc:identifier.uri":["https://scholarbank.nus.edu.sg/bitstreams/7ec1d0e7-1009-4ef3-85ef-fb5630fff113/download"],"dc:relation.isreferencedby":["https://scholarbank.nus.edu.sg/handle/10635/214498"],"dc:subject":["Leukaemia, differentiation, pharmacology, transcription, drugs, cancer"],"dc:title":["MANIPULATING CELL STATES FOR LEUKAEMIA DIFFERENTIATION THERAPY USING NETWORK PHARMACOLOGY"],"dc:type":["Thesis"]},"updated_at":"2026-07-24T03:32:30Z"}